Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na ïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Conditions: Metastatic Colorectal Cancer Interventions: Drug: FOLFIRI Regimen; Drug: Sotorasib; Drug: Panitumumab; Drug: Bevacizumab-awwb Sponsors: Amgen Not yet recruiting

https://clinicaltrials.gov/study/NCT06252649

Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials